Immunai is a biotechnology research company applying single-cell biology, artificial intelligence, immunology, statistical analysis, and genomic technologies to study and reprogram the immune system. Its research aims to uncover therapeutic opportunities and support drug development, with the goal of improving patient outcomes. The company works across biotechnology, healthcare, and pharmaceuticals.
Build reliable, secure agent systems for Immunai’s AI-driven drug discovery platform. Enable autonomous workflows across code, data, pipelines, and computing.